The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Russia's Sputnik V COVID-19 vaccine will cost less than $20 per person internationally

    Synopsis

    The pricing announcement comes as Russia looks to scale up distribution and production. Kirill Dmitriev, head of Russia's RDIF sovereign wealth fund, said Moscow and its foreign partners had capacity to make more than a billion doses starting from next year, enough to vaccinate over 500 million people.

    COVID-19 vaccine: Russia says Sputnik V is over 95% effective, cost of one dose will be less than $10
    Coronavirus

    COVID-19 CASES

    Confirmed
    10,557,985
    Deaths
    152,274
    MOSCOW: Russia's Sputnik V COVID-19 vaccine will cost less than $20 per person on international markets and Moscow aims to produce more than a billion doses at home and abroad next year, its backers and developers said on Tuesday.

    The Sputnik vaccine is administered in two shots, each of which will cost less than $10 each, according to the official Sputnik V Twitter account. For Russian citizens, vaccination will be free of charge.

    The pricing announcement comes as Russia looks to scale up distribution and production. Kirill Dmitriev, head of Russia's RDIF sovereign wealth fund, said Moscow and its foreign partners had capacity to make more than a billion doses starting from next year, enough to vaccinate over 500 million people.

    The international market price for Sputnik V unveiled on Tuesday is cheaper than some other Western rivals such as a vaccine produced by Pfizer-BioNTech, which costs 15.5 euros per shot, but more expensive that a vaccine produced by AstraZeneca which will be sold in Europe for around 2.5 euros per shot.

    Dmitriev told Reuters that Moscow had deliberately tried to get the price down to make it available to as many people around the world as possible.

    RDIF said in a statement: "Sputnik V will be two or more times cheaper than mRNA vaccines with similar efficacy levels."

    It said it was basing its assessment on mRNA vaccines where pricing had already been announced and interim phase three clinical trials were underway.

    RDIF and the Gamaleya National Center said earlier on Tuesday that new clinical trial data based on 39 confirmed cases and 18,794 patients who got both shots had shown that Sputnik V was 91.4% effective on day 28 and over 95% effective on day 42.

    Moscow has been criticised by some scientists in the West who have accused it of cutting corners in an effort to try to rush out the vaccine.

    Russia has denied that, alleging a Western dirty tricks campaign to put people off its vaccine in what it believes has become a battle for legitimacy and market share.

    All you need to know about Russia's Sputnik V coronavirus vaccine which is easier to store

    Autoplay
    1 of 5

    Russia’s Sputnik V

    According to a report by AFP, Russia said Tuesday its Sputnik V coronavirus vaccine was 95 percent effective and would be cheaper and easier to store than some alternatives, as the global race heats up to develop a jab. The announcement was the latest in a flurry of breakthroughs as several vaccine makers worldwide published preliminary data showing efficacy rates of 90 percent and higher.


    (Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    1 Comment on this Story

    Jai Ho54 days ago
    Life has come full circle for some ! Communist are taking on market and Capatalist are looking for govt patronage :-)
    The Economic Times